Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Stock Report: () Report Updated: Nov 10, 2018 | Print This Page

Get more stock ratings by Louis Navellier


Rating: Volatility:
Total Grade: Industry:

Stock Analysis

Rating: Monthly View

November December January February March April May June July August September October

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

Egalet Corporation, a specialty pharmaceutical company, engages in developing, manufacturing, and commercializing medicines for patients with acute and chronic pain. It has licensed two approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; and OXAYDO, an immediate-release oxycodone product formulated to deter abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate. The company also develops a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation using its proprietary Guardian Technology. Its product candidates include Egalet-001 and Egalet-002 that are abuse-deterrent, extended-release, oral formulations for the treatment of moderate and severe pain. The company has a collaboration and license agreement with Shionogi Limited to develop, manufacture, and commercialize abuse-deterrent hydrocodone-based product candidates using its technology. Egalet Corporation was founded in 2010 and is headquartered Wayne, Pennsylvania.